• The purpose of our review is to explore global epidemiologic trends of gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). (nih.gov)
  • PanNETs are a type of neuroendocrine tumor, representing about one-third of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). (wikipedia.org)
  • The World Health Organization (WHO) classification scheme places neuroendocrine tumors into three main categories, which emphasize the tumor grade rather than the anatomical origin. (wikipedia.org)
  • Relative incidence is given as percentage of all functional pancreatic neuroendocrine tumors. (wikipedia.org)
  • The new 2019 WHO classification and grading criteria for neuroendocrine tumors of the digestive system grades all the neuroendocrine tumors into three grades, based on their degree of cellular differentiation (from well-differentiated NET grade (G)1 to G3, and poorly-differentiated neuroendokrina cancer, NEC G3), morphology, mitotic rate and Ki-67 index. (wikipedia.org)
  • Pancreatic neuroendocrine tumor staging (AJCC) Stage T1 Stage T2 Stage T3 Stage T4 Involvement of nearby lymph nodes - Stage N1 Metastasis - stage M1 In general, treatment for PanNET encompasses the same array of options as other neuroendocrine tumors, as discussed in that main article. (wikipedia.org)
  • Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a rare, heterogeneous group of tumors that originate from the endocrine system of the gastrointestinal tract and pancreas. (karger.com)
  • GEP-NENs are subdivided according to their differentiation into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). (karger.com)
  • [ 6 ] In its 2015 consensus statement on best practices for pulmonary neuroendocrine tumors, the ENETS noted that tumor grading based on a combination of KI-67, mitotic rate, and necrosis may be of clinical importance but lacks validation. (medscape.com)
  • The addition of durvalumab to tremelimumab showed modest activity in patients with advanced neuroendocrine tumors of gastroenteropancreatic and lung origins. (onclive.com)
  • Colonic neuroendocrine neoplasms (NENs) are relatively rare tumors with an incidence rate of 0.11-0.21/100,000. (biomedcentral.com)
  • Neuroendocrine neoplasms (NENs) are rare tumors originating from neuroendocrine cells and include a series of heterogeneous tumors. (biomedcentral.com)
  • According to the degree of differentiation, NENs have been divided into well differentiated NENs and poorly differentiated NENs in the 2010 World Health Organization classification of tumors of the digestive system, with the former being termed a neuroendocrine tumor (NET), and the latter, a neuroendocrine carcinoma (NEC) [ 1 ]. (biomedcentral.com)
  • In neuroendocrine tumors (NETs), liver metastases (LM) represent the most crucial prognostic factor, irrespective of the primary tumor site. (oaepublish.com)
  • At diagnosis, about 65-95% of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) show hepatic metastasis. (oaepublish.com)
  • Neuroendocrine tumors (NETs) are rare neoplasms originating from diffuse neuroendocrine cells. (oaepublish.com)
  • [ 2 ] Well- to moderately differentiated neuroendocrine neoplasms (WMD-NEN) are a highly heterogeneous group of tumors comprising low-grade (G1) and intermediate-grade (G2) NETs of the gastrointestinal tract, typical and atypical carcinoids of the lung and thymus, and other cancers such as medullary thyroid carcinoma and pheochromocytoma/paraganglioma. (oaepublish.com)
  • Pancreatic neuroendocrine tumors display a range of clinical presentations and outcomes. (unina.it)
  • Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. (unina.it)
  • One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. (unina.it)
  • Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. (unina.it)
  • Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. (unina.it)
  • Eriksson B. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies? (unina.it)
  • O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. (unina.it)
  • Activity of sunitinib in patients with advanced neuroendocrine tumors. (unina.it)
  • Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II trial. (unina.it)
  • Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. (unina.it)
  • Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET). (unina.it)
  • Therapeutic options in patients with advanced-stage gastroenteropancreatic (GEP) neuroendocrine tumors are limited. (snmjournals.org)
  • Therapeutic options in patients with progressive and disseminated metastatic neuroendocrine gastroenteropancreatic (GEP) tumors are often limited, and prognosis is often poor ( 1 , 2 ). (snmjournals.org)
  • Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. (ukw.de)
  • Lymphoma, neuroectodermal tumor of the colon, and gastroenteropancreatic neuroendocrine tumors have also been reported. (medscape.com)
  • GEP-NENs encompass a wide spectrum of entities, from very indolent tumors to highly aggressive carcinomas. (hunimed.eu)
  • In case of neuroendocrine tumors, tumor tissues can be visualized with Ga-68 DOTA-TATE with high sensitivity and specificity, while Lu-177-DOTA-TATE provides for specific and targeted therapies for tumor tissues. (intheranostics.com)
  • Neuroendocrine Tumors of the Bronchopulmonary System (Typical and Atypical Carcinoid Tumors): Current Strategies in Diagnosis and Treatment. (karger.com)
  • Genomic profiles of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) remain insufficiently understood and the genetic alterations associated with drug responses have not been studied. (scienceexhibitions.org)
  • Neuroendocrine Tumors (NETs) are tumours originated from the hormone-producing cells or nerve cells (the neuroendocrine system). (qtinstruments.com)
  • Neuroendocrine Tumors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (harvard.edu)
  • Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. (harvard.edu)
  • Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition. (harvard.edu)
  • This graph shows the total number of publications written about "Neuroendocrine Tumors" by people in Harvard Catalyst Profiles by year, and whether "Neuroendocrine Tumors" was a major or minor topic of these publication. (harvard.edu)
  • Below are the most recent publications written about "Neuroendocrine Tumors" by people in Profiles. (harvard.edu)
  • Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. (harvard.edu)
  • Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors. (harvard.edu)
  • Genome-Wide Association Study Identifies 4 Novel Risk Loci for Small Intestinal Neuroendocrine Tumors Including a Missense Mutation in LGR5. (harvard.edu)
  • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), also known as carcinoids and islet-cell tumors, are tumors of the neuroendocrine cells that occur in the gastrointestinal (GI) tract. (theoncologypharmacist.com)
  • Although relatively rare, GEP-NETs are more common than other tumors of the GI tract, including stomach and pancreatic carcinomas combined. (theoncologypharmacist.com)
  • As a senior consultant of oncology specialized in endcrine tumors and radionuclide therapy, my research focuses on optimizing peptide receptor radionuclide therapy for patients with neuroendocrine tumors. (lu.se)
  • Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time. (ucsf.edu)
  • Neuroendocrine tumors (NET) constitute a heterogeneous group of rare neoplasms, with a sustained increase in incidence in recent years. (ijhsc.com)
  • Neuroendocrine neoplasms are divided into well-differentiated neuroendocrine tumors (WDNET) and poorly differentiated neuroendocrine carcinomas (PDNEC). (ijhsc.com)
  • Arra A, Coso D, Chagas Guimaraes L. SATB.2 is a sensityive for well differentiated neuroendocrine tumors. (ijhsc.com)
  • Aytac E, Ozdemir Y, Ozuner G: Long term outcomes of neuroendocrine carcinomas (high-grade neuroendocrine tumors) of the colon, rectum, and anal canal. (edu.pl)
  • Inherited syndromes involving pancreatic neuroendocrine tumors. (cdc.gov)
  • Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. (cdc.gov)
  • Carcinoid tumors arise from neuroendocrine cells, which are widespread in the human body, especially in the organs derived from the primitive intestine. (medscape.com)
  • The name was chosen to separate these tumors from ordinary malignancies (carcinomas), but by the 1950s, the fact that carcinoids could be malignant was obvious, thanks to Erspamer and Asero (1952), who identified serotonin production by carcinoid tumors. (medscape.com)
  • In 1980, the World Health Organization (WHO) applied the term carcinoid to all tumors of the diffuse endocrine system (synonymous with amine precursor uptake and decarboxylation [APUD] and neuroendocrine cell system). (medscape.com)
  • Multiple endocrine neoplasia, type 1 (MEN 1) is an autosomal dominant syndrome characterized by hyperplasia or adenomas of the parathyroid glands, pancreatic islet cell tumors (also known as pancreatic neuroendocrine tumors), and/or pituitary gland tumors. (msdmanuals.com)
  • Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? (nih.gov)
  • Pancreatic neuroendocrine tumours (PanNETs, PETs, or PNETs), often referred to as "islet cell tumours", or "pancreatic endocrine tumours" are neuroendocrine neoplasms that arise from cells of the endocrine (hormonal) and nervous system within the pancreas. (wikipedia.org)
  • Pancreatic neuroendocrine neoplasms (pNENs) are an increasingly common group of malignancies that arise within the endocrine tissue of the pancreas. (rarediseases.org)
  • Nonfunctioning neuroendocrine neoplasms can still cause symptoms relating to tumor size and location such as obstruction or internal bleeding. (rarediseases.org)
  • The rationale to utilize immune checkpoint blockade in neuroendocrine neoplasms (NENs) has been limited, as these neoplasms typically have low tumor mutational burden, PD-L1 expression, and lymphocyte infiltration. (onclive.com)
  • New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms. (nih.gov)
  • Treatment landscape of advanced high-grade neuroendocrine neoplasms. (nih.gov)
  • Many retrospective studies have confirmed that capecitabine combined with temozolomide is effective in neuroendocrine neoplasms. (viamedica.pl)
  • Treatment options for grade 3 neuroendocrine neoplasms are limited, and the overall prognosis is better in the subgroup of patients with grade 3 neuroendocrine tumours. (viamedica.pl)
  • It was a retrospective study in the population of patients with diagnosed grade 3 neuroendocrine neoplasms of different origin treated with capecitabine and temozolomide. (viamedica.pl)
  • Highly aggressive, poorly differentiated neoplasms were defined as Grade-3 neuroendocrine carcinomas (NECs) when originating from the gastrointestinal tract, or as small- or large-cell NECs when appearing in the lung. (oaepublish.com)
  • The gastroenteropancreatic (GEP) system is the site of origin of about two thirds of all neuroendocrine neoplasms (NENs) of the human body. (hunimed.eu)
  • Imaging of Small-Bowel Neuroendocrine Neoplasms: AJR Expert Panel Narrative Review. (harvard.edu)
  • A different TNM system for PanNETs has been proposed by The European Neuroendocrine Tumor Society. (wikipedia.org)
  • Hürthle cell carcinoma is considered a radiosensitive tumor. (medscape.com)
  • The World Health Organization (WHO) and the European Neuroendocrine Tumor Society (ENETS) both incorporate mitotic count and Ki-67 proliferation for the classification of gastroenteropancreatic NETs (GEP-NETs). (medscape.com)
  • Hepatocellular carcinoma and carcinoid tumor of the pancreas were reported. (medscape.com)
  • To exclude the chance of the event of combined adenocarcinoma neuroendocrine features or both we performed an unbiased pathology review with regards to architecture tumor quality and chromogranin LY317615 synaptophysin and Compact disc56 immunoreactivity by IHC (Supplementary Desk 1). (scienceexhibitions.org)
  • Shape 1 Mutations in 12 LY317615 NET examples Shape 2 Surroundings of cancer-related mutations within 12 GEP-NETs The individual with mutation was 52 years of age and got a metastatic quality 1 neuroendocrine tumor. (scienceexhibitions.org)
  • The patient had a grade 3 neuroendocrine carcinoma with gastric primary tumor location and extensive abdominal lymph node and peritoneal seeding nodule involvement. (scienceexhibitions.org)
  • Sixty-three cases were reclassified, mostly as well-differentiated neuroendocrine tumor (NET) or acinar cell carcinoma, and eliminated. (johnshopkins.edu)
  • Incidental Langerhans cell histiocytosis associated with metastatic neuroendocrine tumor in the adult liver. (ucsf.edu)
  • Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap. (ucsf.edu)
  • Neuroendocrine carcinoma of the colorectum is a kind of malignant tumor composed of neuroendocrine cells, with a unique hormone synthesis and secretory function. (edu.pl)
  • They are one type of gastroenteropancreatic neuroendocrine tumor (GEP-NET), which can also develop in parts of the gastrointestinal tract, usually in the stomach and duodenum. (msdmanuals.com)
  • 3253 - The impact of tumour absorbed dosimetry with survival outcomes after peptide receptor radionuclide therapy in metastatic neuroendocrine tumours. (esmo.org)
  • 5458 - Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen. (esmo.org)
  • Most of the studies focused on grade 1 and grade 2 neuroendocrine tumours, mainly of pancreatic origin. (viamedica.pl)
  • There are limited data regarding the efficacy capecitabine with temozolomide in grade 3 neuroendocrine tumours. (viamedica.pl)
  • The new World Health Organisation 2017 classification distinguished well-differentiated grade 3 neuroendocrine tumours from poorly differentiated grade 3 neuroendocrine carcinomas. (viamedica.pl)
  • This study aimed to evaluate response and survival parameters and compare outcomes of treatment of neuroendocrine tumours and carcinomas. (viamedica.pl)
  • The study included 32 patients with grade 3 neuroendocrine tumours treated with capecitabine and temozolomide. (viamedica.pl)
  • The progression-free survival for patients with neuroendocrine tumours was 15.3 months (95% CI: 3.9-30.4), and for patients with neuroendocrine carcinomas it was 3.3 months (95% CI: 2.5-7.1). (viamedica.pl)
  • Median overall survival was 22 months (95% CI: 11.8-22.0) and 4.6 months (95% CI: 2.2-5.9) for patients with tumours and carcinomas, respectively. (viamedica.pl)
  • However, it's true to say that the prognosis for differentiated Neuroendocrine Carcinomas (NEC) is generally poorer than the less aggressive Neuroendocrine Tumours (NET).Surgery can be of benefit for localized disease after extensive preoperative imaging. (ronnyallan.net)
  • Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT). (harvard.edu)
  • A dosimetric comparison of systemic peptide receptor radionuclide therapy and intra-arterial peptide receptor radionuclide therapy in patients with liver dominant gastroenteropancreatic neuroendocrine tumours. (harvard.edu)
  • G3 neuroendocrine carcinomas have a similar poor prognosis as pancreatic adenocarinomas. (rarediseases.org)
  • The aim of this study was to evaluate the clinicopathological characteristics and prognosis of neuroendocrine carcinoma of the colorectum. (edu.pl)
  • Neuroendocrine carcinoma of the colon lacked specific clinical manifestations, but showed a high degree of malignancy and a poor prognosis. (edu.pl)
  • Poorly differentiated neuroendocrine carcinoma of the pancreas is a highly aggressive neoplasm, with frequent metastases and poor survival. (johnshopkins.edu)
  • Well-differentiated NET and acinar cell carcinoma are often misdiagnosed as poorly differentiated neuroendocrine carcinoma, emphasizing that diagnostic criteria need to be clearly followed to ensure accurate diagnosis. (johnshopkins.edu)
  • Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas. (harvard.edu)
  • Smith J, Reidy-Lagunes D: The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas. (edu.pl)
  • The gastroenteropancreatic NETs (GEP-NETs) are the most common NETs. (oaepublish.com)
  • The most common type is a gastroenteropancreatic (GEP) NET, which accounts for more than 90% of patients with NETs. (intheranostics.com)
  • In addition to GEP-NETs, there are several subtypes of NETs including pheochromocytoma, paraganglioma, medullary thyroid carcinoma, Markel cell carcinoma and bronchial carcinoids. (intheranostics.com)
  • Long-Term Outcomes and Aggressiveness of Hereditary Medullary Thyroid Carcinoma: 40 Years of Experience at One Center. (cdc.gov)
  • Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma. (cdc.gov)
  • Neuroendocrine carcinomas associated with XHIGM are rapidly progressing and have been found in the pancreas, liver, intestine, and lymph nodes. (medscape.com)
  • Hepatocellular Carcinoma (HCC) is the most common type of liver cancer, with approximately 15 new cases diagnosed every day. (nihr.ac.uk)
  • Cutaneous metastases of colonic neuroendocrine carcinomas (NECs) are very infrequent, while cases of scalp metastasis are even fewer. (biomedcentral.com)
  • We have also reviewed the literature concerning gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) in this article. (biomedcentral.com)
  • They originate in neuroendocrine cells, the most common are those of the gastrointestinal system and most are sporadic, although they can be part of hereditary syndromes. (ijhsc.com)
  • 3-5 Thisobser- vationcombinedwiththeirubiquitousdistributioninneuroendo- crine,endocrineandnervoustissuesmakesCgsusefulmarkersof secretion of normal and tumoral neuroendocrine cells. (123dok.net)
  • Treatment strategies for neuroendocrine carcinoma of the upper digestive tract. (nih.gov)
  • This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based on recent developments and study results. (ronnyallan.net)
  • The treatment did not overcome the aggressive character of neuroendocrine carcinomas and resulted in low response and survival outcomes in comparison to those achieved in tumour therapy. (viamedica.pl)
  • Surgical excision is the main treatment for patients with Hürthle cell carcinoma. (medscape.com)
  • thus, radioactive iodide treatment, which is the most useful nonsurgical therapy for recurrent well-differentiated thyroid carcinoma, is not always useful in patients with Hürthle cell carcinoma. (medscape.com)
  • Nevertheless, radioactive iodide treatment is used for most patients with Hürthle cell cancers after total and near-total thyroidectomy and in the treatment of patients with recurrent and metastatic Hürthle cell carcinoma. (medscape.com)
  • Jillard et al reported that post-thyroidectomy 131 I therapy improves survival in patients with Hürthle cell carcinoma. (medscape.com)
  • [ 35 , 36 ] Retinoic acid therapy also may be considered in patients with Hürthle cell carcinoma that does not take up radioactive iodide, although this is not yet a standard form of therapy. (medscape.com)
  • therefore, T4 should be administered to all patients with thyroid carcinoma, regardless of the extent of thyroid surgery and other treatments. (medscape.com)
  • The multicohort study included patients whose disease stemmed from typical/atypical lung carcinoid (cohort 1), grade 1/2 gastrointestinal (cohort 2), grade 1/2 pancreatic (cohort 3), and grade 3 gastroenteropancreatic origins (cohort 4). (onclive.com)
  • To participate in the DUNE trial, patients needed to have advanced NENs of gastroenteropancreatic or lung origin following progression on standard therapies. (onclive.com)
  • Cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy. (pharmaceutical-technology.com)
  • The clinical data on 49 patients treated for neuroendocrine carcinoma of the colorectum from January 1995 to January 2013 were retrospectively analyzed and relevant scientific literature was investigated. (edu.pl)
  • Pancreatic cancer is the fourth leading cause of cancer-related death in the USA and Europe [ 1 ], and it is expected to overtake lung carcinoma as the second leading cause by 2030 [ 2 ]. (hindawi.com)
  • It was also under development for the treatment of relapsed/refractory multiple myeloma, salivary gland, cancer and adenoid cystic carcinoma (ACC). (pharmaceutical-technology.com)
  • Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. (ukw.de)
  • Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer (NMSC) worldwide, in particular, in fair-skinned population and its incidence has been rising over the past several years [ 1 - 3 ]. (hindawi.com)
  • a poorly differentiated Neuroendocrine Cancer, Grade 3 by default. (ronnyallan.net)
  • You'll note the title of this post is 'World Neuroendocrine Cancer Day' and that is because (so called) 'NET Cancer Day' is not good awareness. (ronnyallan.net)
  • One of the many observations I make in my private Neuroendocrine Cancer Facebook group is the misunderstandings caused by the use of non-standard terminology combined with a lack of understanding of what is up to date or not. (ronnyallan.net)
  • Neuroendocrine Cancer - normally slow but don't be fooled! (ronnyallan.net)
  • One such sneaky disease is the lesser-known type of cancer that infiltrated my body - Neuroendocrine Cancer. (ronnyallan.net)
  • The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer. (harvard.edu)
  • Immunogenomic Landscape of Neuroendocrine Prostate Cancer. (harvard.edu)
  • ORAOV1, CCND1, and MIR548K are the driver oncogenes of the 11q13 amplicon in squamous cell carcinoma. (ucsf.edu)
  • The clinicopathologic features and survival of the remaining 44 poorly differentiated neuroendocrine carcinomas were further assessed. (johnshopkins.edu)
  • Individual Participant Data (IPD) Network Meta-Analysis (NWA) of Neoadjuvant Chemo- or Chemoradiotherapy in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma confirms overall survival benefit for both strategies over surgery alone. (esdo.eu)
  • The MANATEC-02 collaborative group conducted an IPD-NWA to evaluate whether neoadjuvant chemotherapy and chemoradiotherapy have a differential effect on survival for esophageal or GEJ carcinoma and, in particular, across histology, location, and sex. (esdo.eu)
  • A total of 107 pancreatic resections originally diagnosed as poorly differentiated neuroendocrine carcinomas were reassessed using the classification and grading (mitotic rate/Ki67 index) criteria put forth by the World Health Organization in 2010 for the gastroenteropancreatic system. (johnshopkins.edu)
  • Oxidative damage has been suggested to play a role in the pathogenesis of basal cell carcinoma (BCC). (hindawi.com)
  • Septic Cervicofacial Phlegmon Following Basal Cell Carcinoma Excision: Life-threatening Complication of Routine Operation in Maxillofacial Surgery? (cancerdiagnosisprognosis.org)
  • Gastric adenocarcinoma with neuroendocrine differentiation: Clinicopathological features and efficacy of modified DCF chemotherapy. (nih.gov)
  • Immunohistochemical labeling for neuroendocrine and acinar differentiation markers was performed. (johnshopkins.edu)
  • A contralateral nodal metastasis (unlike with skin carcinoma of head and neck below) represents a distant metastasis. (cancer.org.au)
  • Genomic Analysis in the Categorization of Poorly Differentiated Primary Liver Carcinomas. (ucsf.edu)
  • Clinical Analysis of Extrapulmonary Neuroendocrine Carcinoma: A Retrospective and Single Institution Experience. (nih.gov)
  • ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. (ukw.de)
  • Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior. (ucsf.edu)
  • A gastric neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment. (nih.gov)
  • Gastric Neuroendocrine Carcinoma with Rapid Progression. (nih.gov)
  • What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? (ukw.de)
  • Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. (unina.it)